Formulation development and evaluation of Piroxicam orodispersible tabletsusing different superdisintegrants

The demand for mouth dissolving tablets has been growing during the last decade, especially for geriatric and pediatric patients who have swallowing difficulties. Piroxicam is a potent antiinflammatory drug used in treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gout disease. In the present work, 9 formulations of Orodispersible tablets of Piroxicam (F1 to F9) were prepared using three different superdisintegrants namely Crospovidone, Croscarmellose sodium and sodium starch glycolate with three concentrations (3% ,4% and 5%) and a control F10 (without superdisintegrant) by direct compression method. The final blend of the drug and excipients were evaluated for powder flow properties, bulk density, tapped density, compressibility index and hausner’s ratio. All the formulations were evaluated for thickness, weight variation, disintegration time, hardness, friability, drug content, wetting time and water absorption ratio. Formulation F3 showed the lowest disintegration time and more water absorption ratio. In-vitro dissolution studies revealed that formulation F3 showed 99.53 % percent drug release at the end of 50 minutes. The short term stability studies for the formulations showed no significant changes in disintegration time, drug content and percentage drug release when stored at 40C±20C , 27°C ±2°C and 450C±20C for 45 days.